JP2003523171A - 乳房の疾患を検出するために有用な試薬と方法 - Google Patents

Info

Publication number

JP2003523171A

JP2003523171A JP2000593138A JP2000593138A JP2003523171A JP 2003523171 A JP2003523171 A JP 2003523171A JP 2000593138 A JP2000593138 A JP 2000593138A JP 2000593138 A JP2000593138 A JP 2000593138A JP 2003523171 A JP2003523171 A JP 2003523171A

Authority

JP

Japan

Prior art keywords

seq

polynucleotide

polypeptide

sequence

antigen

Prior art date

1999-01-19

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Pending

Links

• Espacenet
• Global Dossier
• Discuss

• 208000030270 breast disease Diseases 0.000 title claims abstract description 36
• 238000000034 method Methods 0.000 title claims description 207
• 239000003153 chemical reaction reagent Substances 0.000 title description 73
• 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 336
• 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 253
• 229920001184 polypeptide Polymers 0.000 claims abstract description 225
• 239000002299 complementary DNA Substances 0.000 claims abstract description 52
• 102000040430 polynucleotide Human genes 0.000 claims description 149
• 108091033319 polynucleotide Proteins 0.000 claims description 149
• 239000002157 polynucleotide Substances 0.000 claims description 149
• 108091007433 antigens Proteins 0.000 claims description 124
• 238000012360 testing method Methods 0.000 claims description 123
• 102000036639 antigens Human genes 0.000 claims description 122
• 239000000427 antigen Substances 0.000 claims description 121
• 239000012634 fragment Substances 0.000 claims description 115
• 239000007790 solid phase Substances 0.000 claims description 75
• 150000007523 nucleic acids Chemical class 0.000 claims description 67
• 239000002773 nucleotide Substances 0.000 claims description 65
• 125000003729 nucleotide group Chemical group 0.000 claims description 64
• 238000009739 binding Methods 0.000 claims description 61
• 239000013612 plasmid Substances 0.000 claims description 61
• 108020004414 DNA Proteins 0.000 claims description 60
• 230000027455 binding Effects 0.000 claims description 58
• 230000009870 specific binding Effects 0.000 claims description 54
• 125000003275 alpha amino acid group Chemical group 0.000 claims description 47
• 238000001514 detection method Methods 0.000 claims description 46
• 239000000047 product Substances 0.000 claims description 46
• 230000000295 complement effect Effects 0.000 claims description 40
• 108020004999 messenger RNA Proteins 0.000 claims description 40
• 108091028043 Nucleic acid sequence Proteins 0.000 claims description 36
• 108091034117 Oligonucleotide Proteins 0.000 claims description 36
• FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 33
• 108091093088 Amplicon Proteins 0.000 claims description 32
• 102000039446 nucleic acids Human genes 0.000 claims description 32
• 108020004707 nucleic acids Proteins 0.000 claims description 32
• 230000002163 immunogen Effects 0.000 claims description 20
• 239000013604 expression vector Substances 0.000 claims description 19
• 238000004519 manufacturing process Methods 0.000 claims description 19
• 230000000692 anti-sense effect Effects 0.000 claims description 17
• 108700026244 Open Reading Frames Proteins 0.000 claims description 16
• 238000010839 reverse transcription Methods 0.000 claims description 16
• 239000007795 chemical reaction product Substances 0.000 claims description 14
• JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims description 12
• 239000002250 absorbent Substances 0.000 claims description 7
• 230000002745 absorbent Effects 0.000 claims description 7
• 230000006870 function Effects 0.000 claims description 7
• 238000003259 recombinant expression Methods 0.000 claims description 7
• 230000001105 regulatory effect Effects 0.000 claims description 7
• 230000028993 immune response Effects 0.000 claims description 4
• 108090000623 proteins and genes Proteins 0.000 abstract description 141
• 102000004169 proteins and genes Human genes 0.000 abstract description 97
• 210000000481 breast Anatomy 0.000 abstract description 70
• 208000026310 Breast neoplasm Diseases 0.000 abstract description 61
• 206010006187 Breast cancer Diseases 0.000 abstract description 60
• 238000011282 treatment Methods 0.000 abstract description 13
• 239000003112 inhibitor Substances 0.000 abstract description 11
• 230000000694 effects Effects 0.000 abstract description 10
• 238000012544 monitoring process Methods 0.000 abstract description 7
• 238000011503 in vivo imaging Methods 0.000 abstract description 5
• 230000001225 therapeutic effect Effects 0.000 abstract description 5
• 239000000556 agonist Substances 0.000 abstract description 2
• 206010027454 Metastases to breast Diseases 0.000 abstract 1
• 239000000523 sample Substances 0.000 description 206
• 210000004027 cell Anatomy 0.000 description 147
• 210000001519 tissue Anatomy 0.000 description 98
• 235000018102 proteins Nutrition 0.000 description 84
• 239000013615 primer Substances 0.000 description 82
• 108091032973 (ribonucleotides)n+m Proteins 0.000 description 70
• 238000003556 assay Methods 0.000 description 69
• 239000013598 vector Substances 0.000 description 62
• 238000003199 nucleic acid amplification method Methods 0.000 description 57
• 230000003321 amplification Effects 0.000 description 56
• 230000014509 gene expression Effects 0.000 description 48
• 238000009396 hybridization Methods 0.000 description 45
• 238000003752 polymerase chain reaction Methods 0.000 description 40
• 239000000203 mixture Substances 0.000 description 39
• 239000000243 solution Substances 0.000 description 39
• 206010028980 Neoplasm Diseases 0.000 description 34
• 239000000126 substance Substances 0.000 description 32
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 32
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 29
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 29
• 229940024606 amino acid Drugs 0.000 description 29
• 235000001014 amino acid Nutrition 0.000 description 29
• 238000004458 analytical method Methods 0.000 description 29
• 150000001413 amino acids Chemical class 0.000 description 28
• 150000001875 compounds Chemical class 0.000 description 28
• 239000012491 analyte Substances 0.000 description 27
• 238000006243 chemical reaction Methods 0.000 description 27
• 108091026890 Coding region Proteins 0.000 description 25
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 24
• 210000004369 blood Anatomy 0.000 description 23
• 239000008280 blood Substances 0.000 description 23
• 239000000499 gel Substances 0.000 description 23
• 241001465754 Metazoa Species 0.000 description 22
• 239000000872 buffer Substances 0.000 description 22
• 201000010099 disease Diseases 0.000 description 22
• 239000011859 microparticle Substances 0.000 description 22
• 102000004190 Enzymes Human genes 0.000 description 21
• 108090000790 Enzymes Proteins 0.000 description 21
• 201000011510 cancer Diseases 0.000 description 21
• 239000002987 primer (paints) Substances 0.000 description 21
• 239000000284 extract Substances 0.000 description 20
• 239000000463 material Substances 0.000 description 20
• 210000002966 serum Anatomy 0.000 description 20
• 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 18
• 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 18
• 238000005516 engineering process Methods 0.000 description 18
• 230000003053 immunization Effects 0.000 description 18
• 238000002649 immunization Methods 0.000 description 18
• 239000003550 marker Substances 0.000 description 18
• 238000000746 purification Methods 0.000 description 18
• 239000011780 sodium chloride Substances 0.000 description 17
• IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 16
• 239000006228 supernatant Substances 0.000 description 16
• WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 15
• 108091035707 Consensus sequence Proteins 0.000 description 15
• 108091060211 Expressed sequence tag Proteins 0.000 description 15
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 15
• 238000002820 assay format Methods 0.000 description 15
• 238000001890 transfection Methods 0.000 description 15
• 210000002700 urine Anatomy 0.000 description 15
• KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 14
• 241000282414 Homo sapiens Species 0.000 description 14
• 230000029087 digestion Effects 0.000 description 14
• 239000003623 enhancer Substances 0.000 description 14
• 239000011541 reaction mixture Substances 0.000 description 14
• 238000013518 transcription Methods 0.000 description 14
• 230000035897 transcription Effects 0.000 description 14
• ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 13
• 241000283973 Oryctolagus cuniculus Species 0.000 description 13
• 238000010240 RT-PCR analysis Methods 0.000 description 13
• 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 13
• 239000002609 medium Substances 0.000 description 13
• 239000012528 membrane Substances 0.000 description 13
• QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 12
• 241000588724 Escherichia coli Species 0.000 description 12
• 208000026062 Tissue disease Diseases 0.000 description 12
• 230000001580 bacterial effect Effects 0.000 description 12
• 239000003795 chemical substances by application Substances 0.000 description 12
• 238000003018 immunoassay Methods 0.000 description 12
• 230000000087 stabilizing effect Effects 0.000 description 12
• 239000011324 bead Substances 0.000 description 11
• 238000003745 diagnosis Methods 0.000 description 11
• 230000010076 replication Effects 0.000 description 11
• HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 10
• 241000701022 Cytomegalovirus Species 0.000 description 10
• DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 10
• 229930006000 Sucrose Natural products 0.000 description 10
• CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 10
• XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 10
• 239000011543 agarose gel Substances 0.000 description 10
• 230000015572 biosynthetic process Effects 0.000 description 10
• 238000005119 centrifugation Methods 0.000 description 10
• 210000004408 hybridoma Anatomy 0.000 description 10
• 238000001727 in vivo Methods 0.000 description 10
• 238000002372 labelling Methods 0.000 description 10
• 238000007834 ligase chain reaction Methods 0.000 description 10
• KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 10
• 230000005291 magnetic effect Effects 0.000 description 10
• 238000012163 sequencing technique Methods 0.000 description 10
• 238000010561 standard procedure Methods 0.000 description 10
• 239000005720 sucrose Substances 0.000 description 10
• 238000013519 translation Methods 0.000 description 10
• 108091003079 Bovine Serum Albumin Proteins 0.000 description 9
• 241000699670 Mus sp. Species 0.000 description 9
• 238000010367 cloning Methods 0.000 description 9
• 210000001072 colon Anatomy 0.000 description 9
• 239000003814 drug Substances 0.000 description 9
• 210000004072 lung Anatomy 0.000 description 9
• 239000000123 paper Substances 0.000 description 9
• 239000008188 pellet Substances 0.000 description 9
• 210000003296 saliva Anatomy 0.000 description 9
• 238000005406 washing Methods 0.000 description 9
• 241000894006 Bacteria Species 0.000 description 8
• 241000283707 Capra Species 0.000 description 8
• 108020004705 Codon Proteins 0.000 description 8
• 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 8
• 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 8
• 238000000636 Northern blotting Methods 0.000 description 8
• ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 8
• 125000000539 amino acid group Chemical group 0.000 description 8
• 239000005557 antagonist Substances 0.000 description 8
• 238000004113 cell culture Methods 0.000 description 8
• OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 8
• 239000001963 growth medium Substances 0.000 description 8
• 230000001900 immune effect Effects 0.000 description 8
• PHTQWCKDNZKARW-UHFFFAOYSA-N isoamylol Chemical compound CC(C)CCO PHTQWCKDNZKARW-UHFFFAOYSA-N 0.000 description 8
• 210000004962 mammalian cell Anatomy 0.000 description 8
• 230000004048 modification Effects 0.000 description 8
• 238000012986 modification Methods 0.000 description 8
• 238000002360 preparation method Methods 0.000 description 8
• 108091008146 restriction endonucleases Proteins 0.000 description 8
• 238000003786 synthesis reaction Methods 0.000 description 8
• 238000001262 western blot Methods 0.000 description 8
• 241000699666 Mus <mouse, genus> Species 0.000 description 7
• 108091081021 Sense strand Proteins 0.000 description 7
• DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 7
• 238000007792 addition Methods 0.000 description 7
• 238000013459 approach Methods 0.000 description 7
• 238000002405 diagnostic procedure Methods 0.000 description 7
• 238000011534 incubation Methods 0.000 description 7
• 239000011572 manganese Substances 0.000 description 7
• 239000012071 phase Substances 0.000 description 7
• 229920003023 plastic Polymers 0.000 description 7
• 239000004033 plastic Substances 0.000 description 7
• 102000005962 receptors Human genes 0.000 description 7
• 238000012216 screening Methods 0.000 description 7
• YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical group N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 6
• 206010003445 Ascites Diseases 0.000 description 6
• 108010022366 Carcinoembryonic Antigen Proteins 0.000 description 6
• 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 description 6
• 206010027476 Metastases Diseases 0.000 description 6
• 239000000020 Nitrocellulose Substances 0.000 description 6
• 239000007983 Tris buffer Substances 0.000 description 6
• 229960000723 ampicillin Drugs 0.000 description 6
• AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 6
• 238000003149 assay kit Methods 0.000 description 6
• 210000001124 body fluid Anatomy 0.000 description 6
• 238000004587 chromatography analysis Methods 0.000 description 6
• 238000000576 coating method Methods 0.000 description 6
• 239000003184 complementary RNA Substances 0.000 description 6
• 239000000562 conjugate Substances 0.000 description 6
• 239000008367 deionised water Substances 0.000 description 6
• 229910021641 deionized water Inorganic materials 0.000 description 6
• 229940079593 drug Drugs 0.000 description 6
• 210000003527 eukaryotic cell Anatomy 0.000 description 6
• 102000037865 fusion proteins Human genes 0.000 description 6
• 108020001507 fusion proteins Proteins 0.000 description 6
• 239000011521 glass Substances 0.000 description 6
• 229910052751 metal Inorganic materials 0.000 description 6
• 239000002184 metal Substances 0.000 description 6
• 229920001220 nitrocellulos Polymers 0.000 description 6
• 210000002307 prostate Anatomy 0.000 description 6
• -1 pyruvate aldehyde Chemical class 0.000 description 6
• 238000011160 research Methods 0.000 description 6
• 239000011347 resin Substances 0.000 description 6
• 229920005989 resin Polymers 0.000 description 6
• 238000001179 sorption measurement Methods 0.000 description 6
• 238000002560 therapeutic procedure Methods 0.000 description 6
• 150000003573 thiols Chemical class 0.000 description 6
• 238000012546 transfer Methods 0.000 description 6
• LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 6
• 102000002260 Alkaline Phosphatase Human genes 0.000 description 5
• 108020004774 Alkaline Phosphatase Proteins 0.000 description 5
• 108020005544 Antisense RNA Proteins 0.000 description 5
• 206010009944 Colon cancer Diseases 0.000 description 5
• 102100031780 Endonuclease Human genes 0.000 description 5
• 108010067770 Endopeptidase K Proteins 0.000 description 5
• 239000004471 Glycine Substances 0.000 description 5
• 108020004711 Nucleic Acid Probes Proteins 0.000 description 5
• 241001494479 Pecora Species 0.000 description 5
• 239000004793 Polystyrene Substances 0.000 description 5
• 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 5
• 102000006382 Ribonucleases Human genes 0.000 description 5
• 108010083644 Ribonucleases Proteins 0.000 description 5
• 240000004808 Saccharomyces cerevisiae Species 0.000 description 5
• 238000002835 absorbance Methods 0.000 description 5
• 230000002788 anti-peptide Effects 0.000 description 5
• 239000010839 body fluid Substances 0.000 description 5
• 238000004422 calculation algorithm Methods 0.000 description 5
• 239000004202 carbamide Substances 0.000 description 5
• 239000011248 coating agent Substances 0.000 description 5
• 238000010790 dilution Methods 0.000 description 5
• 239000012895 dilution Substances 0.000 description 5
• 238000001962 electrophoresis Methods 0.000 description 5
• ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 5
• 229960005542 ethidium bromide Drugs 0.000 description 5
• 238000000605 extraction Methods 0.000 description 5
• 239000012091 fetal bovine serum Substances 0.000 description 5
• 230000002068 genetic effect Effects 0.000 description 5
• 150000002500 ions Chemical class 0.000 description 5
• 230000002427 irreversible effect Effects 0.000 description 5
• 239000006166 lysate Substances 0.000 description 5
• 238000002844 melting Methods 0.000 description 5
• 230000008018 melting Effects 0.000 description 5
• 239000013642 negative control Substances 0.000 description 5
• 229910052757 nitrogen Inorganic materials 0.000 description 5
• 239000002853 nucleic acid probe Substances 0.000 description 5
• 239000012188 paraffin wax Substances 0.000 description 5
• 230000036961 partial effect Effects 0.000 description 5
• 239000002245 particle Substances 0.000 description 5
• 229920002223 polystyrene Polymers 0.000 description 5
• 230000002441 reversible effect Effects 0.000 description 5
• 238000004621 scanning probe microscopy Methods 0.000 description 5
• 230000028327 secretion Effects 0.000 description 5
• 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 5
• DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 5
• LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 4
• 229920000936 Agarose Polymers 0.000 description 4
• 102100026189 Beta-galactosidase Human genes 0.000 description 4
• 108020004635 Complementary DNA Chemical group 0.000 description 4
• SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 4
• 241000711549 Hepacivirus C Species 0.000 description 4
• 108010001336 Horseradish Peroxidase Proteins 0.000 description 4
• KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
• XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 4
• ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 4
• 229930182816 L-glutamine Natural products 0.000 description 4
• FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 4
• 108090001090 Lectins Proteins 0.000 description 4
• 102000004856 Lectins Human genes 0.000 description 4
• OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 4
• SEQKRHFRPICQDD-UHFFFAOYSA-N N-tris(hydroxymethyl)methylglycine Chemical compound OCC(CO)(CO)[NH2+]CC([O-])=O SEQKRHFRPICQDD-UHFFFAOYSA-N 0.000 description 4
• 102000007079 Peptide Fragments Human genes 0.000 description 4
• 108010033276 Peptide Fragments Proteins 0.000 description 4
• 239000002202 Polyethylene glycol Substances 0.000 description 4
• 108010072866 Prostate-Specific Antigen Proteins 0.000 description 4
• 102100038358 Prostate-specific antigen Human genes 0.000 description 4
• XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 4
• PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 4
• IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 4
• 108090000631 Trypsin Proteins 0.000 description 4
• 102000004142 Trypsin Human genes 0.000 description 4
• 241000700605 Viruses Species 0.000 description 4
• 239000002253 acid Substances 0.000 description 4
• 230000000890 antigenic effect Effects 0.000 description 4
• 239000004599 antimicrobial Substances 0.000 description 4
• 230000009286 beneficial effect Effects 0.000 description 4
• 108010005774 beta-Galactosidase Proteins 0.000 description 4
• 238000010804 cDNA synthesis Methods 0.000 description 4
• 150000001720 carbohydrates Chemical class 0.000 description 4
• 235000014633 carbohydrates Nutrition 0.000 description 4
• 230000002759 chromosomal effect Effects 0.000 description 4
• 238000003776 cleavage reaction Methods 0.000 description 4
• 238000012875 competitive assay Methods 0.000 description 4
• 229960002433 cysteine Drugs 0.000 description 4
• 238000004925 denaturation Methods 0.000 description 4
• 230000036425 denaturation Effects 0.000 description 4
• 210000003743 erythrocyte Anatomy 0.000 description 4
• 239000004744 fabric Substances 0.000 description 4
• 239000011724 folic acid Substances 0.000 description 4
• 235000019152 folic acid Nutrition 0.000 description 4
• 229960000304 folic acid Drugs 0.000 description 4
• 230000004927 fusion Effects 0.000 description 4
• 238000001502 gel electrophoresis Methods 0.000 description 4
• 238000001415 gene therapy Methods 0.000 description 4
• 230000012010 growth Effects 0.000 description 4
• 230000035931 haemagglutination Effects 0.000 description 4
• 125000002887 hydroxy group Chemical group [H]O* 0.000 description 4
• FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 4
• 238000003384 imaging method Methods 0.000 description 4
• 239000007924 injection Substances 0.000 description 4
• 238000002347 injection Methods 0.000 description 4
• 238000003780 insertion Methods 0.000 description 4
• 230000037431 insertion Effects 0.000 description 4
• 238000002955 isolation Methods 0.000 description 4
• 239000004816 latex Substances 0.000 description 4
• 229920000126 latex Polymers 0.000 description 4
• 239000010410 layer Substances 0.000 description 4
• 239000002523 lectin Substances 0.000 description 4
• 239000012139 lysis buffer Substances 0.000 description 4
• 238000009607 mammography Methods 0.000 description 4
• 239000011159 matrix material Substances 0.000 description 4
• 230000001404 mediated effect Effects 0.000 description 4
• 229960000485 methotrexate Drugs 0.000 description 4
• 210000005087 mononuclear cell Anatomy 0.000 description 4
• 230000009871 nonspecific binding Effects 0.000 description 4
• 210000000056 organ Anatomy 0.000 description 4
• 230000003169 placental effect Effects 0.000 description 4
• 210000002381 plasma Anatomy 0.000 description 4
• 229920002401 polyacrylamide Polymers 0.000 description 4
• 229920001223 polyethylene glycol Polymers 0.000 description 4
• 239000002244 precipitate Substances 0.000 description 4
• 239000003755 preservative agent Substances 0.000 description 4
• 230000009257 reactivity Effects 0.000 description 4
• 230000007017 scission Effects 0.000 description 4
• 230000003248 secreting effect Effects 0.000 description 4
• 239000007787 solid Substances 0.000 description 4
• 210000000952 spleen Anatomy 0.000 description 4
• 239000003381 stabilizer Substances 0.000 description 4
• 238000006467 substitution reaction Methods 0.000 description 4
• 239000001226 triphosphate Substances 0.000 description 4
• 235000011178 triphosphate Nutrition 0.000 description 4
• 239000012588 trypsin Substances 0.000 description 4
• 238000002424 x-ray crystallography Methods 0.000 description 4
• KIUMMUBSPKGMOY-UHFFFAOYSA-N 3,3'-Dithiobis(6-nitrobenzoic acid) Chemical compound C1=C([N+]([O-])=O)C(C(=O)O)=CC(SSC=2C=C(C(=CC=2)[N+]([O-])=O)C(O)=O)=C1 KIUMMUBSPKGMOY-UHFFFAOYSA-N 0.000 description 3
• DVLFYONBTKHTER-UHFFFAOYSA-N 3-(N-morpholino)propanesulfonic acid Chemical compound OS(=O)(=O)CCCN1CCOCC1 DVLFYONBTKHTER-UHFFFAOYSA-N 0.000 description 3
• 108010013746 3-deoxy-manno-octulosonate cytidyltransferase Proteins 0.000 description 3
• CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
• 108090001008 Avidin Chemical group 0.000 description 3
• BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 3
• 102000014914 Carrier Proteins Human genes 0.000 description 3
• 102000053602 DNA Human genes 0.000 description 3
• 239000003298 DNA probe Substances 0.000 description 3
• RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
• 241000196324 Embryophyta Species 0.000 description 3
• WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
• 241000238631 Hexapoda Species 0.000 description 3
• 241000700588 Human alphaherpesvirus 1 Species 0.000 description 3
• 108060003951 Immunoglobulin Proteins 0.000 description 3
• OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
• 239000004677 Nylon Substances 0.000 description 3
• CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 3
• 229910019142 PO4 Inorganic materials 0.000 description 3
• 206010035226 Plasma cell myeloma Diseases 0.000 description 3
• 241000276498 Pollachius virens Species 0.000 description 3
• 229920001213 Polysorbate 20 Polymers 0.000 description 3
• 238000002123 RNA extraction Methods 0.000 description 3
• 229920002684 Sepharose Polymers 0.000 description 3
• VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 3
• 102000019197 Superoxide Dismutase Human genes 0.000 description 3
• 108010012715 Superoxide dismutase Proteins 0.000 description 3
• 108010006785 Taq Polymerase Proteins 0.000 description 3
• 108010022394 Threonine synthase Proteins 0.000 description 3
• 239000007997 Tricine buffer Substances 0.000 description 3
• 150000007513 acids Chemical class 0.000 description 3
• 238000001042 affinity chromatography Methods 0.000 description 3
• 238000001261 affinity purification Methods 0.000 description 3
• 238000003491 array Methods 0.000 description 3
• 238000000376 autoradiography Methods 0.000 description 3
• 238000001574 biopsy Methods 0.000 description 3
• 235000020958 biotin Nutrition 0.000 description 3
• 229960002685 biotin Drugs 0.000 description 3
• 239000011616 biotin Substances 0.000 description 3
• 230000000903 blocking effect Effects 0.000 description 3
• 125000002091 cationic group Chemical group 0.000 description 3
• 230000008859 change Effects 0.000 description 3
• 208000029742 colonic neoplasm Diseases 0.000 description 3
• 238000010276 construction Methods 0.000 description 3
• 239000012228 culture supernatant Substances 0.000 description 3
• 235000018417 cysteine Nutrition 0.000 description 3
• XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 3
• 230000003247 decreasing effect Effects 0.000 description 3
• 238000012217 deletion Methods 0.000 description 3
• 230000037430 deletion Effects 0.000 description 3
• 238000013461 design Methods 0.000 description 3
• LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
• 238000009826 distribution Methods 0.000 description 3
• 238000009510 drug design Methods 0.000 description 3
• 239000013613 expression plasmid Substances 0.000 description 3
• 239000012894 fetal calf serum Substances 0.000 description 3
• 239000012530 fluid Substances 0.000 description 3
• RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
• 230000036039 immunity Effects 0.000 description 3
• 102000018358 immunoglobulin Human genes 0.000 description 3
• 238000007901 in situ hybridization Methods 0.000 description 3
• 238000011065 in-situ storage Methods 0.000 description 3
• 230000003993 interaction Effects 0.000 description 3
• 210000003734 kidney Anatomy 0.000 description 3
• 210000001165 lymph node Anatomy 0.000 description 3
• 238000004949 mass spectrometry Methods 0.000 description 3
• 230000009401 metastasis Effects 0.000 description 3
• WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 3
• 201000000050 myeloid neoplasm Diseases 0.000 description 3
• 230000003472 neutralizing effect Effects 0.000 description 3
• 229920001778 nylon Polymers 0.000 description 3
• 210000001672 ovary Anatomy 0.000 description 3
• 230000005298 paramagnetic effect Effects 0.000 description 3
• 239000010452 phosphate Substances 0.000 description 3
• 239000002953 phosphate buffered saline Substances 0.000 description 3
• 150000008300 phosphoramidites Chemical class 0.000 description 3
• 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 3
• 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 3
• 210000002729 polyribosome Anatomy 0.000 description 3
• 239000011148 porous material Substances 0.000 description 3
• 230000002265 prevention Effects 0.000 description 3
• 230000008569 process Effects 0.000 description 3
• 238000001742 protein purification Methods 0.000 description 3
• 230000002285 radioactive effect Effects 0.000 description 3
• 238000010188 recombinant method Methods 0.000 description 3
• 229910052710 silicon Inorganic materials 0.000 description 3
• 239000010703 silicon Substances 0.000 description 3
• 239000001632 sodium acetate Substances 0.000 description 3
• 235000017281 sodium acetate Nutrition 0.000 description 3
• 239000001488 sodium phosphate Substances 0.000 description 3
• 229910000162 sodium phosphate Inorganic materials 0.000 description 3
• 241000894007 species Species 0.000 description 3
• 238000003756 stirring Methods 0.000 description 3
• 239000000758 substrate Substances 0.000 description 3
• 239000003053 toxin Substances 0.000 description 3
• 231100000765 toxin Toxicity 0.000 description 3
• 230000009466 transformation Effects 0.000 description 3
• 230000014621 translational initiation Effects 0.000 description 3
• UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 3
• RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 3
• 241000701161 unidentified adenovirus Species 0.000 description 3
• 239000008096 xylene Substances 0.000 description 3
• QEIFSLUFHRCVQL-UHFFFAOYSA-N (5-bromo-4-chloro-1h-indol-3-yl) hydrogen phosphate;(4-methylphenyl)azanium Chemical compound CC1=CC=C(N)C=C1.C1=C(Br)C(Cl)=C2C(OP(O)(=O)O)=CNC2=C1 QEIFSLUFHRCVQL-UHFFFAOYSA-N 0.000 description 2
• XMTQQYYKAHVGBJ-UHFFFAOYSA-N 3-(3,4-DICHLOROPHENYL)-1,1-DIMETHYLUREA Chemical compound CN(C)C(=O)NC1=CC=C(Cl)C(Cl)=C1 XMTQQYYKAHVGBJ-UHFFFAOYSA-N 0.000 description 2
• QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 2
• UJOBWOGCFQCDNV-UHFFFAOYSA-N 9H-carbazole Chemical compound C1=CC=C2C3=CC=CC=C3NC2=C1 UJOBWOGCFQCDNV-UHFFFAOYSA-N 0.000 description 2
• 108700028369 Alleles Proteins 0.000 description 2
• IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
• 241000713838 Avian myeloblastosis virus Species 0.000 description 2
• DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 2
• 108010078791 Carrier Proteins Proteins 0.000 description 2
• 108020004394 Complementary RNA Proteins 0.000 description 2
• 239000003155 DNA primer Substances 0.000 description 2
• 238000001712 DNA sequencing Methods 0.000 description 2
• 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 2
• 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 2
• 102100024746 Dihydrofolate reductase Human genes 0.000 description 2
• 102100020743 Dipeptidase 1 Human genes 0.000 description 2
• 238000002965 ELISA Methods 0.000 description 2
• 241000206602 Eukaryota Species 0.000 description 2
• 229920001917 Ficoll Polymers 0.000 description 2
• WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
• 101710154606 Hemagglutinin Proteins 0.000 description 2
• 208000032843 Hemorrhage Diseases 0.000 description 2
• 241000282412 Homo Species 0.000 description 2
• UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 2
• 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 2
• 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 2
• 101710125507 Integrase/recombinase Proteins 0.000 description 2
• XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
• HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
• ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
• ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
• 108090000364 Ligases Proteins 0.000 description 2
• 102000003960 Ligases Human genes 0.000 description 2
• 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
• FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
• PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 description 2
• 241000714177 Murine leukemia virus Species 0.000 description 2
• 229930193140 Neomycin Natural products 0.000 description 2
• PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
• 101710163270 Nuclease Proteins 0.000 description 2
• 239000012570 Opti-MEM I medium Substances 0.000 description 2
• 101710093908 Outer capsid protein VP4 Proteins 0.000 description 2
• 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 2
• 108020002230 Pancreatic Ribonuclease Proteins 0.000 description 2
• 102000005891 Pancreatic ribonuclease Human genes 0.000 description 2
• 108091093037 Peptide nucleic acid Proteins 0.000 description 2
• 239000004743 Polypropylene Substances 0.000 description 2
• 206010060862 Prostate cancer Diseases 0.000 description 2
• 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
• 101710176177 Protein A56 Proteins 0.000 description 2
• 108010076504 Protein Sorting Signals Proteins 0.000 description 2
• 239000013614 RNA sample Substances 0.000 description 2
• 108020004511 Recombinant DNA Proteins 0.000 description 2
• 108020005091 Replication Origin Proteins 0.000 description 2
• 241000714474 Rous sarcoma virus Species 0.000 description 2
• 241000607142 Salmonella Species 0.000 description 2
• 241000700584 Simplexvirus Species 0.000 description 2
• 108091081024 Start codon Proteins 0.000 description 2
• UZMAPBJVXOGOFT-UHFFFAOYSA-N Syringetin Natural products COC1=C(O)C(OC)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UZMAPBJVXOGOFT-UHFFFAOYSA-N 0.000 description 2
• 102000006601 Thymidine Kinase Human genes 0.000 description 2
• 108020004440 Thymidine kinase Proteins 0.000 description 2
• 230000009471 action Effects 0.000 description 2
• 230000004913 activation Effects 0.000 description 2
• 239000008186 active pharmaceutical agent Substances 0.000 description 2
• ORILYTVJVMAKLC-UHFFFAOYSA-N adamantane Chemical compound C1C(C2)CC3CC1CC2C3 ORILYTVJVMAKLC-UHFFFAOYSA-N 0.000 description 2
• 208000009956 adenocarcinoma Diseases 0.000 description 2
• 239000002671 adjuvant Substances 0.000 description 2
• 230000008901 benefit Effects 0.000 description 2
• IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 2
• 239000012148 binding buffer Substances 0.000 description 2
• 230000004071 biological effect Effects 0.000 description 2
• 230000000740 bleeding effect Effects 0.000 description 2
• 210000001185 bone marrow Anatomy 0.000 description 2
• UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 2
• AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 2
• 101150102092 ccdB gene Proteins 0.000 description 2
• 239000013592 cell lysate Substances 0.000 description 2
• 230000001413 cellular effect Effects 0.000 description 2
• 238000012512 characterization method Methods 0.000 description 2
• 210000004978 chinese hamster ovary cell Anatomy 0.000 description 2
• 239000012539 chromatography resin Substances 0.000 description 2
• 210000000349 chromosome Anatomy 0.000 description 2
• 238000004140 cleaning Methods 0.000 description 2
• 230000002860 competitive effect Effects 0.000 description 2
• 238000005094 computer simulation Methods 0.000 description 2
• 231100000599 cytotoxic agent Toxicity 0.000 description 2
• KCFYHBSOLOXZIF-UHFFFAOYSA-N dihydrochrysin Natural products COC1=C(O)C(OC)=CC(C2OC3=CC(O)=CC(O)=C3C(=O)C2)=C1 KCFYHBSOLOXZIF-UHFFFAOYSA-N 0.000 description 2
• 102000004419 dihydrofolate reductase Human genes 0.000 description 2
• 108020001096 dihydrofolate reductase Proteins 0.000 description 2
• 238000006073 displacement reaction Methods 0.000 description 2
• 238000010494 dissociation reaction Methods 0.000 description 2
• 230000005593 dissociations Effects 0.000 description 2
• 239000012153 distilled water Substances 0.000 description 2
• VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 2
• 239000000975 dye Substances 0.000 description 2
• 239000012636 effector Substances 0.000 description 2
• 238000010828 elution Methods 0.000 description 2
• 230000001804 emulsifying effect Effects 0.000 description 2
• 239000002532 enzyme inhibitor Substances 0.000 description 2
• 210000002919 epithelial cell Anatomy 0.000 description 2
• 238000002474 experimental method Methods 0.000 description 2
• 238000011049 filling Methods 0.000 description 2
• 238000001914 filtration Methods 0.000 description 2
• GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 2
• 230000013595 glycosylation Effects 0.000 description 2
• 238000006206 glycosylation reaction Methods 0.000 description 2
• 238000004128 high performance liquid chromatography Methods 0.000 description 2
• HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
• 230000002209 hydrophobic effect Effects 0.000 description 2
• 206010020718 hyperplasia Diseases 0.000 description 2
• 230000003100 immobilizing effect Effects 0.000 description 2
• 238000002991 immunohistochemical analysis Methods 0.000 description 2
• 238000000338 in vitro Methods 0.000 description 2
• 238000010348 incorporation Methods 0.000 description 2
• 229910052738 indium Inorganic materials 0.000 description 2
• APFVFJFRJDLVQX-UHFFFAOYSA-N indium atom Chemical compound [In] APFVFJFRJDLVQX-UHFFFAOYSA-N 0.000 description 2
• 230000006698 induction Effects 0.000 description 2
• 238000007912 intraperitoneal administration Methods 0.000 description 2
• 206010073096 invasive lobular breast carcinoma Diseases 0.000 description 2
• 210000004185 liver Anatomy 0.000 description 2
• 230000004807 localization Effects 0.000 description 2
• 201000005202 lung cancer Diseases 0.000 description 2
• 208000020816 lung neoplasm Diseases 0.000 description 2
• 229910052749 magnesium Inorganic materials 0.000 description 2
• 239000011777 magnesium Substances 0.000 description 2
• 238000002595 magnetic resonance imaging Methods 0.000 description 2
• 125000005439 maleimidyl group Chemical group C1(C=CC(N1*)=O)=O 0.000 description 2
• 230000003211 malignant effect Effects 0.000 description 2
• 206010061289 metastatic neoplasm Diseases 0.000 description 2
• 235000013336 milk Nutrition 0.000 description 2
• 210000004080 milk Anatomy 0.000 description 2
• 239000008267 milk Substances 0.000 description 2
• 238000002156 mixing Methods 0.000 description 2
• 238000001823 molecular biology technique Methods 0.000 description 2
• 229960004927 neomycin Drugs 0.000 description 2
• 238000007899 nucleic acid hybridization Methods 0.000 description 2
• 230000001575 pathological effect Effects 0.000 description 2
• 239000013610 patient sample Substances 0.000 description 2
• 239000000863 peptide conjugate Substances 0.000 description 2
• YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
• NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
• 230000008488 polyadenylation Effects 0.000 description 2
• 229920002704 polyhistidine Polymers 0.000 description 2
• 229920001155 polypropylene Polymers 0.000 description 2
• 239000013641 positive control Substances 0.000 description 2
• SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
• 239000002243 precursor Substances 0.000 description 2
• 150000003141 primary amines Chemical class 0.000 description 2
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
• 230000037452 priming Effects 0.000 description 2
• XOJVVFBFDXDTEG-UHFFFAOYSA-N pristane Chemical compound CC(C)CCCC(C)CCCC(C)CCCC(C)C XOJVVFBFDXDTEG-UHFFFAOYSA-N 0.000 description 2
• 210000001236 prokaryotic cell Anatomy 0.000 description 2
• 239000012264 purified product Substances 0.000 description 2
• 238000003127 radioimmunoassay Methods 0.000 description 2
• 230000000306 recurrent effect Effects 0.000 description 2
• 230000002829 reductive effect Effects 0.000 description 2
• 230000000717 retained effect Effects 0.000 description 2
• 238000003757 reverse transcription PCR Methods 0.000 description 2
• 102220240796 rs553605556 Human genes 0.000 description 2
• 150000003839 salts Chemical class 0.000 description 2
• 238000007423 screening assay Methods 0.000 description 2
• 238000000926 separation method Methods 0.000 description 2
• 230000011664 signaling Effects 0.000 description 2
• 238000002603 single-photon emission computed tomography Methods 0.000 description 2
• 238000004513 sizing Methods 0.000 description 2
• 150000003384 small molecules Chemical class 0.000 description 2
• 238000000527 sonication Methods 0.000 description 2
• 230000006641 stabilisation Effects 0.000 description 2
• 238000011105 stabilization Methods 0.000 description 2
• 102000005963 steroid binding proteins Human genes 0.000 description 2
• 108020003178 steroid binding proteins Proteins 0.000 description 2
• 210000002536 stromal cell Anatomy 0.000 description 2
• 238000007920 subcutaneous administration Methods 0.000 description 2
• 239000013589 supplement Substances 0.000 description 2
• 229940124597 therapeutic agent Drugs 0.000 description 2
• 238000005382 thermal cycling Methods 0.000 description 2
• 229940104230 thymidine Drugs 0.000 description 2
• 238000011144 upstream manufacturing Methods 0.000 description 2
• NLIVDORGVGAOOJ-MAHBNPEESA-M xylene cyanol Chemical compound [Na+].C1=C(C)C(NCC)=CC=C1C(\C=1C(=CC(OS([O-])=O)=CC=1)OS([O-])=O)=C\1C=C(C)\C(=[NH+]/CC)\C=C/1 NLIVDORGVGAOOJ-MAHBNPEESA-M 0.000 description 2
• 210000005253 yeast cell Anatomy 0.000 description 2
• DIGQNXIGRZPYDK-WKSCXVIASA-N (2R)-6-amino-2-[[2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-[[(2R,3S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2R)-2-[[2-[[2-[[2-[(2-amino-1-hydroxyethylidene)amino]-3-carboxy-1-hydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1,5-dihydroxy-5-iminopentylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]hexanoic acid Chemical compound C[C@@H]([C@@H](C(=N[C@@H](CS)C(=N[C@@H](C)C(=N[C@@H](CO)C(=NCC(=N[C@@H](CCC(=N)O)C(=NC(CS)C(=N[C@H]([C@H](C)O)C(=N[C@H](CS)C(=N[C@H](CO)C(=NCC(=N[C@H](CS)C(=NCC(=N[C@H](CCCCN)C(=O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)N=C([C@H](CS)N=C([C@H](CO)N=C([C@H](CO)N=C([C@H](C)N=C(CN=C([C@H](CO)N=C([C@H](CS)N=C(CN=C(C(CS)N=C(C(CC(=O)O)N=C(CN)O)O)O)O)O)O)O)O)O)O)O)O DIGQNXIGRZPYDK-WKSCXVIASA-N 0.000 description 1
• WYTZZXDRDKSJID-UHFFFAOYSA-N (3-aminopropyl)triethoxysilane Chemical compound CCO[Si](OCC)(OCC)CCCN WYTZZXDRDKSJID-UHFFFAOYSA-N 0.000 description 1
• 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
• 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
• DHBXNPKRAUYBTH-UHFFFAOYSA-N 1,1-ethanedithiol Chemical compound CC(S)S DHBXNPKRAUYBTH-UHFFFAOYSA-N 0.000 description 1
• GZCWLCBFPRFLKL-UHFFFAOYSA-N 1-prop-2-ynoxypropan-2-ol Chemical compound CC(O)COCC#C GZCWLCBFPRFLKL-UHFFFAOYSA-N 0.000 description 1
• PNDPGZBMCMUPRI-HVTJNCQCSA-N 10043-66-0 Chemical compound [131I][131I] PNDPGZBMCMUPRI-HVTJNCQCSA-N 0.000 description 1
• QTERVOZQCNPERI-UHFFFAOYSA-N 1h-indole;phosphoric acid Chemical compound OP(O)(O)=O.C1=CC=C2NC=CC2=C1 QTERVOZQCNPERI-UHFFFAOYSA-N 0.000 description 1
• JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
• AXAVXPMQTGXXJZ-UHFFFAOYSA-N 2-aminoacetic acid;2-amino-2-(hydroxymethyl)propane-1,3-diol Chemical compound NCC(O)=O.OCC(N)(CO)CO AXAVXPMQTGXXJZ-UHFFFAOYSA-N 0.000 description 1
• FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
• OSJPPGNTCRNQQC-UWTATZPHSA-N 3-phospho-D-glyceric acid Chemical compound OC(=O)[C@H](O)COP(O)(O)=O OSJPPGNTCRNQQC-UWTATZPHSA-N 0.000 description 1
• XZKIHKMTEMTJQX-UHFFFAOYSA-N 4-Nitrophenyl Phosphate Chemical compound OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-N 0.000 description 1
• TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 description 1
• KBDWGFZSICOZSJ-UHFFFAOYSA-N 5-methyl-2,3-dihydro-1H-pyrimidin-4-one Chemical compound N1CNC=C(C1=O)C KBDWGFZSICOZSJ-UHFFFAOYSA-N 0.000 description 1
• PGSPUKDWUHBDKJ-UHFFFAOYSA-N 6,7-dihydro-3h-purin-2-amine Chemical compound C1NC(N)=NC2=C1NC=N2 PGSPUKDWUHBDKJ-UHFFFAOYSA-N 0.000 description 1
• ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
• PLAZXGNBGZYJSA-UHFFFAOYSA-N 9-ethylcarbazole Chemical compound C1=CC=C2N(CC)C3=CC=CC=C3C2=C1 PLAZXGNBGZYJSA-UHFFFAOYSA-N 0.000 description 1
• 102000013563 Acid Phosphatase Human genes 0.000 description 1
• 108010051457 Acid Phosphatase Proteins 0.000 description 1
• HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
• 206010001233 Adenoma benign Diseases 0.000 description 1
• 229920001817 Agar Polymers 0.000 description 1
• 108010088751 Albumins Proteins 0.000 description 1
• 102000009027 Albumins Human genes 0.000 description 1
• 108010025188 Alcohol oxidase Proteins 0.000 description 1
• 108010032595 Antibody Binding Sites Proteins 0.000 description 1
• 108020004491 Antisense DNA Proteins 0.000 description 1
• 108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
• 101100238293 Arabidopsis thaliana MOR1 gene Proteins 0.000 description 1
• 241000972773 Aulopiformes Species 0.000 description 1
• 235000014469 Bacillus subtilis Nutrition 0.000 description 1
• 102000004506 Blood Proteins Human genes 0.000 description 1
• 108010017384 Blood Proteins Proteins 0.000 description 1
• 241000283690 Bos taurus Species 0.000 description 1
• 206010055113 Breast cancer metastatic Diseases 0.000 description 1
• PCDQPRRSZKQHHS-XVFCMESISA-N CTP Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 PCDQPRRSZKQHHS-XVFCMESISA-N 0.000 description 1
• 208000031968 Cadaver Diseases 0.000 description 1
• OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
• BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
• 102100032566 Carbonic anhydrase-related protein 10 Human genes 0.000 description 1
• 108090000994 Catalytic RNA Proteins 0.000 description 1
• 102000053642 Catalytic RNA Human genes 0.000 description 1
• 241000282693 Cercopithecidae Species 0.000 description 1
• 102000011022 Chorionic Gonadotropin Human genes 0.000 description 1
• 108010062540 Chorionic Gonadotropin Proteins 0.000 description 1
• 108091062157 Cis-regulatory element Proteins 0.000 description 1
• KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
• 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
• 241000699802 Cricetulus griseus Species 0.000 description 1
• 101710112752 Cytotoxin Proteins 0.000 description 1
• 101150074155 DHFR gene Proteins 0.000 description 1
• 108010017826 DNA Polymerase I Proteins 0.000 description 1
• 102000004594 DNA Polymerase I Human genes 0.000 description 1
• 108020003215 DNA Probes Proteins 0.000 description 1
• 230000004544 DNA amplification Effects 0.000 description 1
• 230000004543 DNA replication Effects 0.000 description 1
• 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
• 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
• 229920002307 Dextran Polymers 0.000 description 1
• BVTJGGGYKAMDBN-UHFFFAOYSA-N Dioxetane Chemical class C1COO1 BVTJGGGYKAMDBN-UHFFFAOYSA-N 0.000 description 1
• 108090000204 Dipeptidase 1 Proteins 0.000 description 1
• 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
• 208000006402 Ductal Carcinoma Diseases 0.000 description 1
• 101150082674 E2 gene Proteins 0.000 description 1
• 201000009051 Embryonal Carcinoma Diseases 0.000 description 1
• 102100029727 Enteropeptidase Human genes 0.000 description 1
• 108010013369 Enteropeptidase Proteins 0.000 description 1
• 108010074860 Factor Xa Proteins 0.000 description 1
• 208000007659 Fibroadenoma Diseases 0.000 description 1
• 208000000571 Fibrocystic breast disease Diseases 0.000 description 1
• 241000700662 Fowlpox virus Species 0.000 description 1
• 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
• 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
• 244000068988 Glycine max Species 0.000 description 1
• 235000010469 Glycine max Nutrition 0.000 description 1
• 102100036738 Guanine nucleotide-binding protein subunit alpha-11 Human genes 0.000 description 1
• HVLSXIKZNLPZJJ-TXZCQADKSA-N HA peptide Chemical compound C([C@@H](C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 HVLSXIKZNLPZJJ-TXZCQADKSA-N 0.000 description 1
• 239000007995 HEPES buffer Substances 0.000 description 1
• 102000002812 Heat-Shock Proteins Human genes 0.000 description 1
• 108010004889 Heat-Shock Proteins Proteins 0.000 description 1
• 241000700721 Hepatitis B virus Species 0.000 description 1
• 108010093488 His-His-His-His-His-His Proteins 0.000 description 1
• 101000867836 Homo sapiens Carbonic anhydrase-related protein 10 Proteins 0.000 description 1
• 101100283445 Homo sapiens GNA11 gene Proteins 0.000 description 1
• 101000879758 Homo sapiens Sjoegren syndrome nuclear autoantigen 1 Proteins 0.000 description 1
• DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
• 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
• 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
• 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
• 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
• 208000005726 Inflammatory Breast Neoplasms Diseases 0.000 description 1
• 206010021980 Inflammatory carcinoma of the breast Diseases 0.000 description 1
• 208000037396 Intraductal Noninfiltrating Carcinoma Diseases 0.000 description 1
• 206010073094 Intraductal proliferative breast lesion Diseases 0.000 description 1
• 108010025815 Kanamycin Kinase Proteins 0.000 description 1
• AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
• QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
• GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 description 1
• 208000000265 Lobular Carcinoma Diseases 0.000 description 1
• 239000007987 MES buffer Substances 0.000 description 1
• PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
• WAEMQWOKJMHJLA-UHFFFAOYSA-N Manganese(2+) Chemical compound [Mn+2] WAEMQWOKJMHJLA-UHFFFAOYSA-N 0.000 description 1
• 108010063312 Metalloproteins Proteins 0.000 description 1
• 102000010750 Metalloproteins Human genes 0.000 description 1
• 102000003792 Metallothionein Human genes 0.000 description 1
• 108090000157 Metallothionein Proteins 0.000 description 1
• 108700005084 Multigene Family Proteins 0.000 description 1
• 101000969137 Mus musculus Metallothionein-1 Proteins 0.000 description 1
• 101710135898 Myc proto-oncogene protein Proteins 0.000 description 1
• 102100038895 Myc proto-oncogene protein Human genes 0.000 description 1
• NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
• BAWFJGJZGIEFAR-NNYOXOHSSA-N NAD zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-N 0.000 description 1
• 238000005481 NMR spectroscopy Methods 0.000 description 1
• 101000783356 Naja sputatrix Cytotoxin Proteins 0.000 description 1
• 108091005461 Nucleic proteins Proteins 0.000 description 1
• 108020005187 Oligonucleotide Probes Proteins 0.000 description 1
• 108010038807 Oligopeptides Proteins 0.000 description 1
• 102000015636 Oligopeptides Human genes 0.000 description 1
• 241000283977 Oryctolagus Species 0.000 description 1
• 238000012408 PCR amplification Methods 0.000 description 1
• 238000002944 PCR assay Methods 0.000 description 1
• 239000012807 PCR reagent Substances 0.000 description 1
• 229930040373 Paraformaldehyde Natural products 0.000 description 1
• 102000035195 Peptidases Human genes 0.000 description 1
• 108091005804 Peptidases Proteins 0.000 description 1
• 108091000080 Phosphotransferase Proteins 0.000 description 1
• 229920002319 Poly(methyl acrylate) Polymers 0.000 description 1
• 241000288906 Primates Species 0.000 description 1
• 206010036790 Productive cough Diseases 0.000 description 1
• ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
• 239000004365 Protease Substances 0.000 description 1
• 101710130181 Protochlorophyllide reductase A, chloroplastic Proteins 0.000 description 1
• 241000589516 Pseudomonas Species 0.000 description 1
• 241000667869 Psix Species 0.000 description 1
• 108010066717 Q beta Replicase Proteins 0.000 description 1
• 239000012979 RPMI medium Substances 0.000 description 1
• 101001039269 Rattus norvegicus Glycine N-methyltransferase Proteins 0.000 description 1
• 241000220010 Rhode Species 0.000 description 1
• 108091028664 Ribonucleotide Proteins 0.000 description 1
• 241000235070 Saccharomyces Species 0.000 description 1
• 241000293871 Salmonella enterica subsp. enterica serovar Typhi Species 0.000 description 1
• 238000006095 Schwartz hydrozirconation reaction Methods 0.000 description 1
• 229920005654 Sephadex Polymers 0.000 description 1
• 239000012507 Sephadex™ Substances 0.000 description 1
• 238000012300 Sequence Analysis Methods 0.000 description 1
• MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
• 108020004682 Single-Stranded DNA Proteins 0.000 description 1
• 102100037330 Sjoegren syndrome nuclear autoantigen 1 Human genes 0.000 description 1
• 238000002105 Southern blotting Methods 0.000 description 1
• 241000191940 Staphylococcus Species 0.000 description 1
• 241000187747 Streptomyces Species 0.000 description 1
• 241000187180 Streptomyces sp. Species 0.000 description 1
• 241000701093 Suid alphaherpesvirus 1 Species 0.000 description 1
• 101150006914 TRP1 gene Proteins 0.000 description 1
• GKLVYJBZJHMRIY-OUBTZVSYSA-N Technetium-99 Chemical compound [99Tc] GKLVYJBZJHMRIY-OUBTZVSYSA-N 0.000 description 1
• 239000004809 Teflon Substances 0.000 description 1
• 229920006362 Teflon® Polymers 0.000 description 1
• 208000024313 Testicular Neoplasms Diseases 0.000 description 1
• 206010057644 Testis cancer Diseases 0.000 description 1
• 239000004098 Tetracycline Substances 0.000 description 1
• AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
• 239000004473 Threonine Substances 0.000 description 1
• 101710150448 Transcriptional regulator Myc Proteins 0.000 description 1
• 102000004357 Transferases Human genes 0.000 description 1
• 108090000992 Transferases Proteins 0.000 description 1
• QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
• 241000700618 Vaccinia virus Species 0.000 description 1
• 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
• 108020005202 Viral DNA Proteins 0.000 description 1
• 229930003779 Vitamin B12 Natural products 0.000 description 1
• IXKSXJFAGXLQOQ-XISFHERQSA-N WHWLQLKPGQPMY Chemical compound C([C@@H](C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)NC(=O)[C@@H](N)CC=1C2=CC=CC=C2NC=1)C1=CNC=N1 IXKSXJFAGXLQOQ-XISFHERQSA-N 0.000 description 1
• HMNZFMSWFCAGGW-XPWSMXQVSA-N [3-[hydroxy(2-hydroxyethoxy)phosphoryl]oxy-2-[(e)-octadec-9-enoyl]oxypropyl] (e)-octadec-9-enoate Chemical compound CCCCCCCC\C=C\CCCCCCCC(=O)OCC(COP(O)(=O)OCCO)OC(=O)CCCCCCC\C=C\CCCCCCCC HMNZFMSWFCAGGW-XPWSMXQVSA-N 0.000 description 1
• 230000001594 aberrant effect Effects 0.000 description 1
• 230000002159 abnormal effect Effects 0.000 description 1
• 230000005856 abnormality Effects 0.000 description 1
• 238000010521 absorption reaction Methods 0.000 description 1
• 230000021736 acetylation Effects 0.000 description 1
• 238000006640 acetylation reaction Methods 0.000 description 1
• 239000012445 acidic reagent Substances 0.000 description 1
• DZBUGLKDJFMEHC-UHFFFAOYSA-O acridine;hydron Chemical compound C1=CC=CC2=CC3=CC=CC=C3[NH+]=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-O 0.000 description 1
• 238000000787 affinity precipitation Methods 0.000 description 1
• 239000008272 agar Substances 0.000 description 1
• 238000000246 agarose gel electrophoresis Methods 0.000 description 1
• 238000011256 aggressive treatment Methods 0.000 description 1
• 238000013019 agitation Methods 0.000 description 1
• 230000029936 alkylation Effects 0.000 description 1
• 238000005804 alkylation reaction Methods 0.000 description 1
• 230000004075 alteration Effects 0.000 description 1
• 150000001412 amines Chemical class 0.000 description 1
• 125000003277 amino group Chemical group 0.000 description 1
• 229960003896 aminopterin Drugs 0.000 description 1
• BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
• 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
• 238000012870 ammonium sulfate precipitation Methods 0.000 description 1
• 235000011130 ammonium sulphate Nutrition 0.000 description 1
• 210000004102 animal cell Anatomy 0.000 description 1
• 238000005571 anion exchange chromatography Methods 0.000 description 1
• 150000001450 anions Chemical class 0.000 description 1
• 230000001745 anti-biotin effect Effects 0.000 description 1
• 239000003816 antisense DNA Substances 0.000 description 1
• 239000000074 antisense oligonucleotide Substances 0.000 description 1
• 238000012230 antisense oligonucleotides Methods 0.000 description 1
• 239000007864 aqueous solution Substances 0.000 description 1
• 238000004630 atomic force microscopy Methods 0.000 description 1
• 210000003719 b-lymphocyte Anatomy 0.000 description 1
• 108010058966 bacteriophage T7 induced DNA polymerase Proteins 0.000 description 1
• WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
• AFYNADDZULBEJA-UHFFFAOYSA-N bicinchoninic acid Chemical compound C1=CC=CC2=NC(C=3C=C(C4=CC=CC=C4N=3)C(=O)O)=CC(C(O)=O)=C21 AFYNADDZULBEJA-UHFFFAOYSA-N 0.000 description 1
• 108091008324 binding proteins Proteins 0.000 description 1
• 230000003115 biocidal effect Effects 0.000 description 1
• 230000004791 biological behavior Effects 0.000 description 1
• 239000013060 biological fluid Substances 0.000 description 1
• 239000012472 biological sample Substances 0.000 description 1
• 239000002981 blocking agent Substances 0.000 description 1
• 238000009835 boiling Methods 0.000 description 1
• 238000007469 bone scintigraphy Methods 0.000 description 1
• 239000012888 bovine serum Substances 0.000 description 1
• 229940098773 bovine serum albumin Drugs 0.000 description 1
• 210000004556 brain Anatomy 0.000 description 1
• 201000008274 breast adenocarcinoma Diseases 0.000 description 1
• 210000000069 breast epithelial cell Anatomy 0.000 description 1
• 201000003149 breast fibroadenoma Diseases 0.000 description 1
• 201000003714 breast lobular carcinoma Diseases 0.000 description 1
• 239000007975 buffered saline Substances 0.000 description 1
• 229910052791 calcium Inorganic materials 0.000 description 1
• 239000011575 calcium Substances 0.000 description 1
• 229910001424 calcium ion Inorganic materials 0.000 description 1
• 239000001506 calcium phosphate Substances 0.000 description 1
• 229910000389 calcium phosphate Inorganic materials 0.000 description 1
• 235000011010 calcium phosphates Nutrition 0.000 description 1
• 229910002091 carbon monoxide Inorganic materials 0.000 description 1
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
• 239000002340 cardiotoxin Substances 0.000 description 1
• 231100000677 cardiotoxin Toxicity 0.000 description 1
• 239000003054 catalyst Substances 0.000 description 1
• 238000005277 cation exchange chromatography Methods 0.000 description 1
• 108091092328 cellular RNA Proteins 0.000 description 1
• 239000001913 cellulose Substances 0.000 description 1
• 229920002678 cellulose Polymers 0.000 description 1
• 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
• 230000003196 chaotropic effect Effects 0.000 description 1
• 239000013522 chelant Substances 0.000 description 1
• 239000002738 chelating agent Substances 0.000 description 1
• 238000001311 chemical methods and process Methods 0.000 description 1
• 238000002038 chemiluminescence detection Methods 0.000 description 1
• 210000000038 chest Anatomy 0.000 description 1
• 229960005091 chloramphenicol Drugs 0.000 description 1
• 239000002026 chloroform extract Substances 0.000 description 1
• YTRQFSDWAXHJCC-UHFFFAOYSA-N chloroform;phenol Chemical compound ClC(Cl)Cl.OC1=CC=CC=C1 YTRQFSDWAXHJCC-UHFFFAOYSA-N 0.000 description 1
• 239000003593 chromogenic compound Substances 0.000 description 1
• 239000013599 cloning vector Substances 0.000 description 1
• AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
• 210000004922 colonic epithelial cell Anatomy 0.000 description 1
• 238000004440 column chromatography Methods 0.000 description 1
• 230000009137 competitive binding Effects 0.000 description 1
• 230000009918 complex formation Effects 0.000 description 1
• 230000000536 complexating effect Effects 0.000 description 1
• 238000004590 computer program Methods 0.000 description 1
• 239000003636 conditioned culture medium Substances 0.000 description 1
• 230000001268 conjugating effect Effects 0.000 description 1
• 230000021615 conjugation Effects 0.000 description 1
• 238000011437 continuous method Methods 0.000 description 1
• 238000007796 conventional method Methods 0.000 description 1
• 238000001816 cooling Methods 0.000 description 1
• RYGMFSIKBFXOCR-AKLPVKDBSA-N copper-67 Chemical compound [67Cu] RYGMFSIKBFXOCR-AKLPVKDBSA-N 0.000 description 1
• 230000008878 coupling Effects 0.000 description 1
• 239000007822 coupling agent Substances 0.000 description 1
• 238000010168 coupling process Methods 0.000 description 1
• 238000005859 coupling reaction Methods 0.000 description 1
• 238000004132 cross linking Methods 0.000 description 1
• 238000009295 crossflow filtration Methods 0.000 description 1
• 239000000287 crude extract Substances 0.000 description 1
• 239000013078 crystal Substances 0.000 description 1
• 238000012258 culturing Methods 0.000 description 1
• 238000005520 cutting process Methods 0.000 description 1
• ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
• 230000001351 cycling effect Effects 0.000 description 1
• 230000000093 cytochemical effect Effects 0.000 description 1
• 230000009089 cytolysis Effects 0.000 description 1
• 210000000805 cytoplasm Anatomy 0.000 description 1
• 231100000433 cytotoxic Toxicity 0.000 description 1
• 229940127089 cytotoxic agent Drugs 0.000 description 1
• 239000002254 cytotoxic agent Substances 0.000 description 1
• 230000001472 cytotoxic effect Effects 0.000 description 1
• 239000002619 cytotoxin Substances 0.000 description 1
• SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 1
• SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 1
• RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 1
• HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 1
• 230000034994 death Effects 0.000 description 1
• 231100000517 death Toxicity 0.000 description 1
• 238000010908 decantation Methods 0.000 description 1
• 230000002950 deficient Effects 0.000 description 1
• 229940124447 delivery agent Drugs 0.000 description 1
• 239000005547 deoxyribonucleotide Substances 0.000 description 1
• 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
• 238000010511 deprotection reaction Methods 0.000 description 1
• 238000011161 development Methods 0.000 description 1
• 229960002086 dextran Drugs 0.000 description 1
• 229960000633 dextran sulfate Drugs 0.000 description 1
• 239000008121 dextrose Substances 0.000 description 1
• 238000000502 dialysis Methods 0.000 description 1
• 238000002050 diffraction method Methods 0.000 description 1
• 208000035475 disorder Diseases 0.000 description 1
• 239000003937 drug carrier Substances 0.000 description 1
• 238000007877 drug screening Methods 0.000 description 1
• 238000002651 drug therapy Methods 0.000 description 1
• 208000028715 ductal breast carcinoma in situ Diseases 0.000 description 1
• 201000007273 ductal carcinoma in situ Diseases 0.000 description 1
• 238000004520 electroporation Methods 0.000 description 1
• 239000012877 elongation medium Substances 0.000 description 1
• 239000000839 emulsion Substances 0.000 description 1
• 230000007515 enzymatic degradation Effects 0.000 description 1
• 238000006911 enzymatic reaction Methods 0.000 description 1
• 238000009585 enzyme analysis Methods 0.000 description 1
• 238000012869 ethanol precipitation Methods 0.000 description 1
• DNJIEGIFACGWOD-UHFFFAOYSA-N ethyl mercaptane Natural products CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 description 1
• 238000011156 evaluation Methods 0.000 description 1
• 108010052305 exodeoxyribonuclease III Proteins 0.000 description 1
• 210000003608 fece Anatomy 0.000 description 1
• 210000002950 fibroblast Anatomy 0.000 description 1
• 239000000706 filtrate Substances 0.000 description 1
• 239000012467 final product Substances 0.000 description 1
• 239000012847 fine chemical Substances 0.000 description 1
• 239000000834 fixative Substances 0.000 description 1
• 210000001559 fluids and secretion Anatomy 0.000 description 1
• 238000001917 fluorescence detection Methods 0.000 description 1
• 238000002875 fluorescence polarization Methods 0.000 description 1
• 239000007850 fluorescent dye Substances 0.000 description 1
• MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 description 1
• 238000009472 formulation Methods 0.000 description 1
• 230000002538 fungal effect Effects 0.000 description 1
• RJOJUSXNYCILHH-UHFFFAOYSA-N gadolinium(3+) Chemical compound [Gd+3] RJOJUSXNYCILHH-UHFFFAOYSA-N 0.000 description 1
• 238000004817 gas chromatography Methods 0.000 description 1
• 210000001035 gastrointestinal tract Anatomy 0.000 description 1
• 101150056310 gem1 gene Proteins 0.000 description 1
• 230000002414 glycolytic effect Effects 0.000 description 1
• PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
• ZJYYHGLJYGJLLN-UHFFFAOYSA-N guanidinium thiocyanate Chemical compound SC#N.NC(N)=N ZJYYHGLJYGJLLN-UHFFFAOYSA-N 0.000 description 1
• 238000003306 harvesting Methods 0.000 description 1
• 238000010438 heat treatment Methods 0.000 description 1
• 239000000185 hemagglutinin Substances 0.000 description 1
• 108060003552 hemocyanin Proteins 0.000 description 1
• 210000003701 histiocyte Anatomy 0.000 description 1
• 238000000265 homogenisation Methods 0.000 description 1
• 229940084986 human chorionic gonadotropin Drugs 0.000 description 1
• 238000004191 hydrophobic interaction chromatography Methods 0.000 description 1
• 229910052588 hydroxylapatite Inorganic materials 0.000 description 1
• 230000002390 hyperplastic effect Effects 0.000 description 1
• 238000005286 illumination Methods 0.000 description 1
• 210000004201 immune sera Anatomy 0.000 description 1
• 229940042743 immune sera Drugs 0.000 description 1
• 230000000984 immunochemical effect Effects 0.000 description 1
• 229940127121 immunoconjugate Drugs 0.000 description 1
• 229940027941 immunoglobulin g Drugs 0.000 description 1
• 230000016784 immunoglobulin production Effects 0.000 description 1
• 238000013115 immunohistochemical detection Methods 0.000 description 1
• 238000003364 immunohistochemistry Methods 0.000 description 1
• 238000010324 immunological assay Methods 0.000 description 1
• 230000006872 improvement Effects 0.000 description 1
• 201000004653 inflammatory breast carcinoma Diseases 0.000 description 1
• 206010022000 influenza Diseases 0.000 description 1
• 239000004615 ingredient Substances 0.000 description 1
• 230000005764 inhibitory process Effects 0.000 description 1
• 238000011221 initial treatment Methods 0.000 description 1
• 238000011081 inoculation Methods 0.000 description 1
• 239000000138 intercalating agent Substances 0.000 description 1
• 230000002452 interceptive effect Effects 0.000 description 1
• 238000007918 intramuscular administration Methods 0.000 description 1
• 239000007927 intramuscular injection Substances 0.000 description 1
• 238000010255 intramuscular injection Methods 0.000 description 1
• 239000007928 intraperitoneal injection Substances 0.000 description 1
• 238000001990 intravenous administration Methods 0.000 description 1
• 229940029329 intrinsic factor Drugs 0.000 description 1
• 230000009545 invasion Effects 0.000 description 1
• 208000030776 invasive breast carcinoma Diseases 0.000 description 1
• 206010073095 invasive ductal breast carcinoma Diseases 0.000 description 1
• 201000010985 invasive ductal carcinoma Diseases 0.000 description 1
• 239000011630 iodine Substances 0.000 description 1
• 229910052740 iodine Inorganic materials 0.000 description 1
• PGLTVOMIXTUURA-UHFFFAOYSA-N iodoacetamide Chemical compound NC(=O)CI PGLTVOMIXTUURA-UHFFFAOYSA-N 0.000 description 1
• 238000004255 ion exchange chromatography Methods 0.000 description 1
• 229910052742 iron Inorganic materials 0.000 description 1
• 229960000310 isoleucine Drugs 0.000 description 1
• AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
• BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
• 229960000318 kanamycin Drugs 0.000 description 1
• 229930027917 kanamycin Natural products 0.000 description 1
• SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
• 229930182823 kanamycin A Natural products 0.000 description 1
• 210000003292 kidney cell Anatomy 0.000 description 1
• 101150109249 lacI gene Proteins 0.000 description 1
• 101150066555 lacZ gene Proteins 0.000 description 1
• 238000011031 large-scale manufacturing process Methods 0.000 description 1
• 231100000518 lethal Toxicity 0.000 description 1
• 230000001665 lethal effect Effects 0.000 description 1
• 210000000265 leukocyte Anatomy 0.000 description 1
• GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 1
• 108010052968 leupeptin Proteins 0.000 description 1
• 239000003446 ligand Substances 0.000 description 1
• 239000002502 liposome Substances 0.000 description 1
• 239000007788 liquid Substances 0.000 description 1
• 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
• 239000007791 liquid phase Substances 0.000 description 1
• 238000007449 liver function test Methods 0.000 description 1
• 244000144972 livestock Species 0.000 description 1
• 239000012160 loading buffer Substances 0.000 description 1
• 230000007774 longterm Effects 0.000 description 1
• HWYHZTIRURJOHG-UHFFFAOYSA-N luminol Chemical compound O=C1NNC(=O)C2=C1C(N)=CC=C2 HWYHZTIRURJOHG-UHFFFAOYSA-N 0.000 description 1
• 210000002751 lymph Anatomy 0.000 description 1
• 230000002934 lysing effect Effects 0.000 description 1
• 210000002540 macrophage Anatomy 0.000 description 1
• 239000006249 magnetic particle Substances 0.000 description 1
• 238000012423 maintenance Methods 0.000 description 1
• 230000014759 maintenance of location Effects 0.000 description 1
• 230000036210 malignancy Effects 0.000 description 1
• 210000001161 mammalian embryo Anatomy 0.000 description 1
• 238000007726 management method Methods 0.000 description 1
• 229910052748 manganese Inorganic materials 0.000 description 1
• 238000001819 mass spectrum Methods 0.000 description 1
• 238000005259 measurement Methods 0.000 description 1
• 201000001441 melanoma Diseases 0.000 description 1
• QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
• 229910052753 mercury Inorganic materials 0.000 description 1
• 150000002739 metals Chemical class 0.000 description 1
• 230000001394 metastastic effect Effects 0.000 description 1
• 229930182817 methionine Natural products 0.000 description 1
• YACKEPLHDIMKIO-UHFFFAOYSA-N methylphosphonic acid Chemical compound CP(O)(O)=O YACKEPLHDIMKIO-UHFFFAOYSA-N 0.000 description 1
• 108091070501 miRNA Proteins 0.000 description 1
• 230000000813 microbial effect Effects 0.000 description 1
• 244000005700 microbiome Species 0.000 description 1
• 238000002324 minimally invasive surgery Methods 0.000 description 1
• 238000010369 molecular cloning Methods 0.000 description 1
• 238000000329 molecular dynamics simulation Methods 0.000 description 1
• 239000003068 molecular probe Substances 0.000 description 1
• 210000001616 monocyte Anatomy 0.000 description 1
• 239000000178 monomer Substances 0.000 description 1
• 125000004573 morpholin-4-yl group Chemical class N1(CCOCC1)* 0.000 description 1
• 150000002780 morpholines Chemical class 0.000 description 1
• 201000010879 mucinous adenocarcinoma Diseases 0.000 description 1
• 210000003205 muscle Anatomy 0.000 description 1
• 238000002703 mutagenesis Methods 0.000 description 1
• 231100000350 mutagenesis Toxicity 0.000 description 1
• 238000001186 nanoelectrospray ionisation mass spectrometry Methods 0.000 description 1
• 238000013188 needle biopsy Methods 0.000 description 1
• 210000000440 neutrophil Anatomy 0.000 description 1
• 229910052759 nickel Inorganic materials 0.000 description 1
• 229940101270 nicotinamide adenine dinucleotide (nad) Drugs 0.000 description 1
• 230000001293 nucleolytic effect Effects 0.000 description 1
• 210000004940 nucleus Anatomy 0.000 description 1
• 235000015097 nutrients Nutrition 0.000 description 1
• 239000002751 oligonucleotide probe Substances 0.000 description 1
• 238000011275 oncology therapy Methods 0.000 description 1
• 108091008819 oncoproteins Proteins 0.000 description 1
• 102000027450 oncoproteins Human genes 0.000 description 1
• 230000003287 optical effect Effects 0.000 description 1
• 238000011369 optimal treatment Methods 0.000 description 1
• 229920002866 paraformaldehyde Polymers 0.000 description 1
• 238000012335 pathological evaluation Methods 0.000 description 1
• 230000037361 pathway Effects 0.000 description 1
• XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
• 238000005897 peptide coupling reaction Methods 0.000 description 1
• 238000012510 peptide mapping method Methods 0.000 description 1
• 210000001322 periplasm Anatomy 0.000 description 1
• 150000002978 peroxides Chemical class 0.000 description 1
• 235000020030 perry Nutrition 0.000 description 1
• 230000002085 persistent effect Effects 0.000 description 1
• 239000008363 phosphate buffer Substances 0.000 description 1
• 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
• 229940080469 phosphocellulose Drugs 0.000 description 1
• PTMHPRAIXMAOOB-UHFFFAOYSA-L phosphoramidate Chemical compound NP([O-])([O-])=O PTMHPRAIXMAOOB-UHFFFAOYSA-L 0.000 description 1
• 230000026731 phosphorylation Effects 0.000 description 1
• 238000006366 phosphorylation reaction Methods 0.000 description 1
• 102000020233 phosphotransferase Human genes 0.000 description 1
• 230000000704 physical effect Effects 0.000 description 1
• 210000002826 placenta Anatomy 0.000 description 1
• 238000013492 plasmid preparation Methods 0.000 description 1
• 239000013600 plasmid vector Substances 0.000 description 1
• 229920000447 polyanionic polymer Polymers 0.000 description 1
• 229920000867 polyelectrolyte Polymers 0.000 description 1
• 229920000642 polymer Polymers 0.000 description 1
• 238000006116 polymerization reaction Methods 0.000 description 1
• 229940051841 polyoxyethylene ether Drugs 0.000 description 1
• 229920000056 polyoxyethylene ether Polymers 0.000 description 1
• 238000002600 positron emission tomography Methods 0.000 description 1
• 230000004481 post-translational protein modification Effects 0.000 description 1
• 239000000843 powder Substances 0.000 description 1
• 238000001556 precipitation Methods 0.000 description 1
• 238000002953 preparative HPLC Methods 0.000 description 1
• 238000012545 processing Methods 0.000 description 1
• 229940002612 prodrug Drugs 0.000 description 1
• 239000000651 prodrug Substances 0.000 description 1
• 238000004393 prognosis Methods 0.000 description 1
• 208000037821 progressive disease Diseases 0.000 description 1
• 238000011321 prophylaxis Methods 0.000 description 1
• 208000017497 prostate disease Diseases 0.000 description 1
• 235000019419 proteases Nutrition 0.000 description 1
• 230000012846 protein folding Effects 0.000 description 1
• 239000012474 protein marker Substances 0.000 description 1
• 230000030788 protein refolding Effects 0.000 description 1
• 239000012460 protein solution Substances 0.000 description 1
• 229940124272 protein stabilizer Drugs 0.000 description 1
• 230000012743 protein tagging Effects 0.000 description 1
• 230000002797 proteolythic effect Effects 0.000 description 1
• 150000003230 pyrimidines Chemical class 0.000 description 1
• 239000000376 reactant Substances 0.000 description 1
• 230000006798 recombination Effects 0.000 description 1
• 238000005215 recombination Methods 0.000 description 1
• 238000011084 recovery Methods 0.000 description 1
• 239000001044 red dye Substances 0.000 description 1
• 230000009467 reduction Effects 0.000 description 1
• 238000002271 resection Methods 0.000 description 1
• 210000002345 respiratory system Anatomy 0.000 description 1
• 230000004044 response Effects 0.000 description 1
• 238000004007 reversed phase HPLC Methods 0.000 description 1
• WUAPFZMCVAUBPE-IGMARMGPSA-N rhenium-186 Chemical compound [186Re] WUAPFZMCVAUBPE-IGMARMGPSA-N 0.000 description 1
• PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
• 239000003161 ribonuclease inhibitor Substances 0.000 description 1
• 239000002336 ribonucleotide Substances 0.000 description 1
• 125000002652 ribonucleotide group Chemical group 0.000 description 1
• 108020004418 ribosomal RNA Proteins 0.000 description 1
• 108091092562 ribozyme Proteins 0.000 description 1
• 235000019515 salmon Nutrition 0.000 description 1
• 239000012723 sample buffer Substances 0.000 description 1
• 229920006298 saran Polymers 0.000 description 1
• 210000000582 semen Anatomy 0.000 description 1
• 230000035945 sensitivity Effects 0.000 description 1
• 238000002864 sequence alignment Methods 0.000 description 1
• 239000012679 serum free medium Substances 0.000 description 1
• 239000002356 single layer Substances 0.000 description 1
• 235000020183 skimmed milk Nutrition 0.000 description 1
• 238000002791 soaking Methods 0.000 description 1
• 239000011734 sodium Substances 0.000 description 1
• 229910052708 sodium Inorganic materials 0.000 description 1
• 238000002764 solid phase assay Methods 0.000 description 1
• 239000002904 solvent Substances 0.000 description 1
• 238000002798 spectrophotometry method Methods 0.000 description 1
• 238000004611 spectroscopical analysis Methods 0.000 description 1
• 210000004988 splenocyte Anatomy 0.000 description 1
• 239000007921 spray Substances 0.000 description 1
• 210000003802 sputum Anatomy 0.000 description 1
• 208000024794 sputum Diseases 0.000 description 1
• 238000010186 staining Methods 0.000 description 1
• 239000011550 stock solution Substances 0.000 description 1
• 210000002784 stomach Anatomy 0.000 description 1
• 238000003860 storage Methods 0.000 description 1
• 239000007929 subcutaneous injection Substances 0.000 description 1
• 125000001424 substituent group Chemical group 0.000 description 1
• GPTONYMQFTZPKC-UHFFFAOYSA-N sulfamethoxydiazine Chemical compound N1=CC(OC)=CN=C1NS(=O)(=O)C1=CC=C(N)C=C1 GPTONYMQFTZPKC-UHFFFAOYSA-N 0.000 description 1
• 239000004094 surface-active agent Substances 0.000 description 1
• 238000001356 surgical procedure Methods 0.000 description 1
• 230000004083 survival effect Effects 0.000 description 1
• 239000000725 suspension Substances 0.000 description 1
• 230000002194 synthesizing effect Effects 0.000 description 1
• 230000009885 systemic effect Effects 0.000 description 1
• 238000004885 tandem mass spectrometry Methods 0.000 description 1
• 210000001138 tear Anatomy 0.000 description 1
• 229940056501 technetium 99m Drugs 0.000 description 1
• 238000010998 test method Methods 0.000 description 1
• 201000003120 testicular cancer Diseases 0.000 description 1
• 229960002180 tetracycline Drugs 0.000 description 1
• 229930101283 tetracycline Natural products 0.000 description 1
• 235000019364 tetracycline Nutrition 0.000 description 1
• 150000003522 tetracyclines Chemical class 0.000 description 1
• SRVJKTDHMYAMHA-WUXMJOGZSA-N thioacetazone Chemical compound CC(=O)NC1=CC=C(\C=N\NC(N)=S)C=C1 SRVJKTDHMYAMHA-WUXMJOGZSA-N 0.000 description 1
• HNKJADCVZUBCPG-UHFFFAOYSA-N thioanisole Chemical compound CSC1=CC=CC=C1 HNKJADCVZUBCPG-UHFFFAOYSA-N 0.000 description 1
• 125000003396 thiol group Chemical group [H]S* 0.000 description 1
• 239000003106 tissue adhesive Substances 0.000 description 1
• 231100000419 toxicity Toxicity 0.000 description 1
• 230000001988 toxicity Effects 0.000 description 1
• 230000005758 transcription activity Effects 0.000 description 1
• 230000005030 transcription termination Effects 0.000 description 1
• 230000026683 transduction Effects 0.000 description 1
• 238000010361 transduction Methods 0.000 description 1
• 230000009261 transgenic effect Effects 0.000 description 1
• 230000001052 transient effect Effects 0.000 description 1
• 230000032258 transport Effects 0.000 description 1
• 238000001926 trapping method Methods 0.000 description 1
• QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
• ZSDSQXJSNMTJDA-UHFFFAOYSA-N trifluralin Chemical compound CCCN(CCC)C1=C([N+]([O-])=O)C=C(C(F)(F)F)C=C1[N+]([O-])=O ZSDSQXJSNMTJDA-UHFFFAOYSA-N 0.000 description 1
• 125000002264 triphosphate group Chemical class [H]OP(=O)(O[H])OP(=O)(O[H])OP(=O)(O[H])O* 0.000 description 1
• 201000007423 tubular adenocarcinoma Diseases 0.000 description 1
• 210000004231 tunica media Anatomy 0.000 description 1
• 230000005641 tunneling Effects 0.000 description 1
• 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 1
• 241001515965 unidentified phage Species 0.000 description 1
• 241001430294 unidentified retrovirus Species 0.000 description 1
• 150000003672 ureas Chemical class 0.000 description 1
• 239000003981 vehicle Substances 0.000 description 1
• 239000013603 viral vector Substances 0.000 description 1
• 230000003612 virological effect Effects 0.000 description 1
• 238000012800 visualization Methods 0.000 description 1
• 239000011715 vitamin B12 Substances 0.000 description 1
• 235000019163 vitamin B12 Nutrition 0.000 description 1
• 239000011534 wash buffer Substances 0.000 description 1
• 238000005303 weighing Methods 0.000 description 1